The same class of medications that has transformed the treatment of diabetes and obesity is now showing potential in a different realm of medicine: the treatment of addiction. For years, patients taking GLP-1 receptor agonists like semaglutide and tirzepatide reported an unexpected side effect—a decreased interest in alcohol and nicotine. Now, a large-scale study published in The BMJ provides data-driven weight to these anecdotes, suggesting these drugs may target a common biological pathway underlying various forms of dependency.
Researchers analyzed the electronic health records of more than 600,000 patients within the U.S. Veterans Affairs health system over a three-year period. The study found that patients prescribed GLP-1 medications for type 2 diabetes had a 14% lower overall risk of developing a new substance use disorder compared to those on other diabetes treatments. This reduction was consistent across several substances, including an 18% lower risk for alcohol, 20% for nicotine and cocaine, and a 25% lower risk for opioid use disorders.
The study’s findings were particularly notable for those already living with a substance use disorder. In this group, the use of GLP-1 medications was associated with significantly fewer life-threatening events, including a 39% reduction in overdoses and a 50% reduction in drug-related deaths. While the researchers emphasize that these results show an association rather than a direct cause-and-effect link, the consistency of the data across multiple outcomes suggests the medications may be addressing a fundamental aspect of addiction biology.
This research marks a potential shift in how society approaches addiction, moving away from viewing it as a moral failing toward treating it as a manageable health condition. While clinicians caution that randomized controlled trials are still necessary to confirm these benefits and determine ideal dosages, the study offers hope for a more unified approach to treatment. Instead of addressing each addiction individually, medicine may be moving toward targeting the shared biological signal of craving itself, providing a new tool for millions of people navigating the complexities of recovery.
